Clovis Oncology

Realizing the promise of personalized medicines for cancer

Clovis Oncology (NASDAQ: CLVS) is developing targeted cancer therapies in combination with companion diagnostics to ensure that the right drug gets to the right patients. The company achieved FDA approval for Rubraca (rucaparib) in 2016 to treat women with advanced ovarian cancer whose tumors have a BRCA mutation. Clovis completed its IPO in 2011.

Status

IPO in 2011 (NASDAQ: CLVS)

Year of Investment

2009

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Boulder, Colorado

Social Media